| 2025-12-01 |
详情>>
内部人交易：
Liu Dongfang共交易2笔
|
| 2025-11-03 |
详情>>
股本变动：
变动后总股本34283.34万股
|
| 2025-11-03 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.49美元,归母净利润-1.68亿美元,同比去年增长67.59%
|
| 2025-11-03 |
财报披露：
美东时间 2025-11-03 盘后发布财报
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-0.33美元,归母净利润-1.12亿美元,同比去年增长76.48%
|
| 2025-06-12 |
复牌提示：
2025-06-11 12:55:42 停牌，复牌日期 2025-06-11 13:39:13
|
| 2025-05-07 |
详情>>
业绩披露：
2025年一季报每股收益-0.16美元,归母净利润-5323.6万美元,同比去年增长-259.9%
|
| 2025-04-08 |
股东大会：
将于2025-05-21召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ two nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the 2028 Annual Meeting and their successors are duly elected and qualified. Holders of Class A Stock and holders of Class B Stock voting together as one class will elect one director, and holders of Class B Stock will elect one director.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2025-03-06 |
详情>>
业绩披露：
2024年年报每股收益-2.11美元,归母净利润-5.68亿美元,同比去年增长-649.24%
|
| 2024-11-06 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.11美元,归母净利润-5.18亿美元,同比去年增长-736.08%
|
| 2024-08-05 |
详情>>
业绩披露：
2024年中报每股收益-2.06美元,归母净利润-4.77亿美元,同比去年增长-1026.57%
|
| 2024-07-30 |
股东大会：
将于2024-09-03召开股东大会
会议内容 ▼▲
- 1.To elect the Board of Directors’ two nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the 2027 Annual Meeting and their successors are duly elected and qualified. Holders of Class A Stock will elect one director and holders of Class B Stock will elect one director.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.
4.To approve conversion of the outstanding shares of Series A Preferred Stock to Class A Stock.
5.To approve an adjournment of the Annual Meeting, if necessary or appropriate, to solicit additional proxies.
6.To conduct any other business properly brought before the Annual Meeting.
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.07美元,归母净利润-1479.2万美元,同比去年增长31.92%
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-0.35美元,归母净利润-7580.2万美元,同比去年增长27.25%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.28美元,归母净利润-6201.5万美元,同比去年增长25.60%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-0.19美元,归母净利润-4236.6万美元,同比去年增长24.55%
|
| 2023-04-04 |
股东大会：
将于2023-05-15召开股东大会
会议内容 ▼▲
- 1.To elect the two nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the 2026 Annual Meeting and their successors are dulyelected and qualified. Holders of Class A Stock will elect one director and holders of Class B Stock will elect one director.Holders of Class A Stock and holders of Class B Stock will vote together as one class on all other proposals.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement.
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2022-04-04 |
股东大会：
将于2022-05-16召开股东大会
会议内容 ▼▲
- 1.To elect the three nominees for director named in the proxy statement accompanying this Notice of Annual Meeting of Stockholders (the Proxy Statement) to serve until the 2025 Annual Meeting and their successors are duly elected and qualified. Holders of Class A Stock will elect two directors and holders of Class B Stock will elect one director.Holders of Class A Stock and holders of Class B Stock will vote together as one class on all other proposals.
2.To ratify the selection of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To indicate, on an advisory basis, the preferred frequency of the stockholders’ advisory votes on the compensation of the Company’s named executive officers.
4.To conduct any other business properly brought before the Annual Meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-01-20 |
股东大会：
将于2021-02-09召开股东大会
会议内容 ▼▲
- 1.The Business Combination Proposal-To consider and vote upon a proposal to approve the merger agreement and the Business Combination. A copy of the merger agreement is attached to this proxy statement/prospectus as Annex A (the “Business Combination Proposal”);
2.The Charter Proposals-To consider and vote upon amendments to Panacea ’s current amended and restated certificate of incorporation (the “existing charter”) to be filed as a new amended and restated certificate of incorporation (the “proposed charter”). The proposed amendments detailed below will be voted on separately and are collectively referred to as the “Charter Proposals.”;
2.1.Name Change Charter Amendment-change the corporate name from “Panacea Acquisition Corp.” to “Nuvation Bio Inc.”;
2.2.Purpose Charter Amendment-eliminate certain provisions related to the purpose of special purpose acquisition corporations that will no longer be relevant following the closing of the merger;
2.3.Authorized Shares Charter Amendment-increase the number of authorized shares of Class A common stock from 500,000,000 to 1,000,000,000 and increase the number of authorized shares of Class B common stock from 20,000,000 to 60,000,000;
2.4.Rights of Class B Common Stock Charter Amendment-provide that the holders of New Nuvation Bio Class B common stock are entitled to elect three directors of New Nuvation Bio or, if applicable, a greater number of directors, and that a majority of the New Nuvation Bio Class B common stock be required to approve any liquidation event, so long as any shares of New Nuvation Bio Class B common stock are outstanding;
2.5.Blank Check Preferred Stock Charter Amendment-authorize the issuance of up to 10,000,000 shares of “blank check” preferred stock;
2.6.Actions by Stockholders Charter Amendment-provide that no action shall be taken by stockholders of New Nuvation Bio, except at an annual or special meeting of the stockholders;
2.7.Corporate Opportunity Doctrine Charter Amendment-remove limitations on the corporate opportunity doctrine;
2.8.Voting Thresholds Charter Amendment-(i) increase the required voting thresholds for approving certain amendments to the proposed charter and any amendments to the New Nuvation Bio bylaws to 662/3% and (ii) provide that any amendment to the proposed charter that adversely affects the New Nuvation Bio Class B common stock requires majority approval by its holders;
2.9.Additional Charter Amendment-approve all other changes, including eliminating certain provisions related to special purpose acquisition corporations that will no longer be relevant following the closing of the merger;
3.The NYSE Proposal-To consider and vote upon a proposal to approve, for purposes of complying with applicable listing rules of the New York Stock Exchange (the “NYSE”), (a) the issuance of approximately 91,301,000 shares of New Nuvation Bio Class A common stock and approximately 57,584,000 shares of New Nuvation Bio Class B common stock (together with the reservation of additional shares of New Nuvation Bio Class A common stock for issuance in respect of certain options issued in exchange for outstanding pre-merger Nuvation Bio options) in accordance with the terms of the merger agreement; (b) the issuance and sale of 47,655,000 shares of New Nuvation Bio Class A common stock in the PIPE investment (as defined below) to certain investors, (c) the issuance and sale of 2,500,000 forward purchase units, consisting of 2,500,000 shares of New Nuvation Bio Class A common stock and warrants to purchase 833,333 shares of New Nuvation Bio Class A common stock to funds affiliated with EcoR1 Capital, LLC, pursuant to that certain forward purchase agreement, dated as of June 30, 2020, and (d) the issuance and sale of such additional shares of New Nuvation Bio Class A common stock as EcoR1 Panacea Holdings, LLC and its affiliates may elect to purchase in order to satisfy the minimum cash closing condition as set forth in the merger agreement (the “NYSE Proposal”);
4.The Incentive Plan Proposal-To consider and vote upon a proposal to approve and adopt the 2021 Equity Incentive Plan (the “2021 Plan”), including the authorization of the initial share reserve under the 2021 Plan (the “Incentive Plan Proposal”);
5.The ESPP Proposal-To consider and vote upon a proposal to approve and adopt the Employee Stock Purchase Plan (the “2021 ESPP”), including the authorization of the initial share reserve under the 2021 ESPP (the “ESPP Proposal”);
6.The Adjournment Proposal- To consider and vote upon a proposal to adjourn the Panacea Special Meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the Panacea Special Meeting, there are not sufficient votes to approve the Business Combination Proposal, the Charter Proposals, the NYSE Proposal, the Incentive Plan Proposal or the ESPP Proposal, or holders of Panacea’s public shares have elected to redeem a number of public shares such that Panacea would have less than $5,000,001 of net tangible assets or the amount in the Trust Account (as defined below), plus the proceeds from the PIPE investment, plus the proceeds from the forward purchase agreement entered into in connection with Panacea’s initial public offering (“Panacea’s IPO”), plus all other cash and cash equivalents of Panacea (after deducting the cash amounts required to satisfy Panacea’s stockholder redemptions and transaction costs) does not equal or exceed $500.0 million; provided that to the extent David Hung, M.D., the founder, President and Chief Executive Officer of Nuvation Bio, has not fulfilled his contractual commitment to fund at least $20.0 million of the PIPE investment, then the cash closing requirement shall be reduced dollar for dollar by the amount of such shortfall (the “Adjournment Proposal”).
|